Healthcare Industry News: Spine Wave
News Release - October 23, 2012
Spine Wave Announces Growth of Product PortfolioAcquisition of Santa Clara Technology Inc. and Limited Market Release of StaXx(R) XD Expandable 15 Degree Lordotic Device
SHELTON, CT--(Healthcare Sales & Marketing Network) - Spine Wave, Inc. today announced the addition of two new offerings within its expandable product portfolio. Spine Wave has completed a definitive agreement to acquire Santa Clara Technology Inc. The versatile technology developed by SCT provides a unique expandable titanium interbody cage platform, which can be used in a variety of clinical applications. Additionally, Spine Wave has initiated the limited market release of the StaXx® XD 15° Lordotic Expandable Device.
Additionally, Mr. Pafford commented that "the Company is initiating a limited market release of the StaXx® XD 15° Lordotic Expandable Device to provide spine surgeons with a novel clinical approach to address sagittal balance with a less invasive means to achieving segmental lordosis. We are excited about the potential for this technology and expect full commercialization of this important device in early 2013."
"In 2012 we have been able to achieve significant revenue growth through a rapid expansion of our independent distribution network," said Mark LoGuidice, Spine Wave Chairman and CEO. "Through internal development efforts, the SCT acquisition, and in collaboration with the Memphis based R&D company, MB Innovations, we expect to introduce several important and novel product solutions in 2013 and beyond. The robust R&D pipeline and the continued focus on expanding our distribution channel has us very excited about our future growth opportunities."
About Spine Wave
Spine Wave's product portfolio features many highly differentiated technologies including the flagship product, the StaXx® XD Expandable Device, which has a four year proven track record for posterior surgery. The StaXx® XD family of products includes StaXx® XDL which is intended to be implanted using a lateral surgical approach. In addition to the expandable technologies, the Sniper® Spine System has quickly developed a reputation as a leading MIS screw system and the recently enhanced CapSure® PS3 Spine System is proving to be a high quality, traditional screw system with an expanded offering for complex surgery. The Company continues to advance the NuCore® Injectable Nucleus technology in a European clinical study designed to treat early stage DDD via a percutaneous injection. For further information on all of the Spine Wave products please visit the Company's website at www.SpineWave.com.
Source: Spine Wave
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.